Praxis Precision Medicines, Inc. financial data

Symbol
PRAX on Nasdaq
Industry
Pharmaceutical Preparations
Location
99 High Street, 30 Th Floor, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.21K % +156%
Debt-to-equity 7.71 % -74.8%
Return On Equity -49.5 % +67.2%
Return On Assets -46 % +60.2%
Operating Margin -2.34K % +54.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20.2M shares +52.3%
Common Stock, Shares, Outstanding 19.4M shares +121%
Entity Public Float 733M USD +397%
Common Stock, Value, Issued 14K USD +7.69%
Weighted Average Number of Shares Outstanding, Basic 17.9M shares +172%
Weighted Average Number of Shares Outstanding, Diluted 17.9M shares +172%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 8.55M USD +250%
Research and Development Expense 152M USD +75.7%
General and Administrative Expense 56.3M USD +33.9%
Operating Income (Loss) -200M USD -58.4%
Nonoperating Income (Expense) 17.3M USD +460%
Net Income (Loss) Attributable to Parent -183M USD -48.3%
Earnings Per Share, Basic -10.2 USD/shares +45.4%
Earnings Per Share, Diluted -10.2 USD/shares +45.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 215M USD +165%
Cash, Cash Equivalents, and Short-term Investments 470M USD
Assets, Current 404M USD +376%
Property, Plant and Equipment, Net 230K USD -60.9%
Operating Lease, Right-of-Use Asset 1.13M USD -45.2%
Other Assets, Noncurrent 416K USD 0%
Assets 483M USD +449%
Accounts Payable, Current 12.5M USD +115%
Accrued Liabilities, Current 23.8M USD +220%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 37.6M USD +138%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 110K USD -92%
Liabilities 37.7M USD +106%
Accumulated Other Comprehensive Income (Loss), Net of Tax 654K USD
Retained Earnings (Accumulated Deficit) -837M USD -28%
Stockholders' Equity Attributable to Parent 445M USD +539%
Liabilities and Equity 483M USD +449%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.9M USD +36.5%
Net Cash Provided by (Used in) Financing Activities 183M USD +911%
Net Cash Provided by (Used in) Investing Activities -91.2M USD -368%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 19.4M shares +121%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 70.7M USD +268%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 216M USD +164%
Deferred Tax Assets, Valuation Allowance 218M USD +20.9%
Deferred Tax Assets, Gross 219M USD +20.7%
Operating Lease, Liability 1.37M USD -45.1%
Depreciation 112K USD +5.66%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -182M USD -48%
Lessee, Operating Lease, Liability, to be Paid 1.43M USD -47.5%
Property, Plant and Equipment, Gross 1.59M USD 0%
Operating Lease, Liability, Current 1.26M USD +11.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 110K USD -91.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.32M USD +1.93%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 62K USD -73.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 110K USD -91.7%
Deferred Tax Assets, Operating Loss Carryforwards 90.1M USD +20.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 1.28B USD +77.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 284K USD -49.2%
Share-based Payment Arrangement, Expense 41.4M USD +66.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%